Skip to main content
Clinical Trials/EUCTR2017-002437-36-IT
EUCTR2017-002437-36-ITActive, not recruitingPhase 1

Pilot study to evaluate the feasibility of an innovative approach to monitor patients with gastrointestinal stromal tumour treated with imatinib - Innovative approach to monitor GIST patients treated with imatinib

CENTRO DI RIFERIMENTO ONCOLOGICO0 sites58 target enrollmentStarted: September 7, 2021Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
58

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • Histologically or cytologically confirmed diagnosis of metastatic GIST eligible for imatinib treatment according to the routine clinical practice criteria; Age =18; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with adequate liver, renal and bone marrow functions; Life expectancy > 3 months; Just for patients already on-treatment with imatinib, the therapy must be initiated more than 3 months prior to the first sample collection (to reach a stable blood drug concentration); Signed informed consent and local Ethical Committee (EC) approval availability; All patients in fertile age must have been under contraceptive treatment;
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 18

Exclusion Criteria

  • Pregnancy status; Refusal of informed consent; non-collaborative and/or unreliable patients; Patients who could not attend periodic clinical check-ups.

Investigators

Similar Trials